Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Car-Nk Cells for Haematological Cancers Publisher



Noorafrooz M1 ; Gale RP2 ; Noorafrooz R1 ; Ghods S1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Vali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, United Kingdom

Source: Best Practice and Research: Clinical Haematology Published:2025


Abstract

Chimeric antigen receptor-natural-killer (CAR-NK)-cells are a promising cancer cell therapy. Several features of CAR-NK-cells are suggesting an advantage over CAR-T-cells such as less complex manufacturing, “off-the-shelf” use and lower risks of cytokine release (CRS) and immune effector cell-associated neurotoxicity syndromes (ICANS). CAR-NK-cells derived from several sources are associated with promising pre-clinical and clinical results in haematological cancers. We comprehensively discuss the current landscape of CAR-NK-cell therapy in haematological cancers emphasizing recent progress and future directions. Additionally, we explore the biological mechanisms, engineering and sources of CAR-NK-cells. CAR-NK-cell therapy offers a safe, accessible and efficient option for haematological cancers. © 2025 Elsevier Ltd
Related Docs
View other Related Docs
1. Novel Gene Manipulation Approaches to Unlock the Existing Bottlenecks of Car-Nk Cell Therapy, Frontiers in Cell and Developmental Biology (2024)
2. Chimeric Antigen Receptor-Natural Killer Cells: A Promising Sword Against Insidious Tumor Cells, Human Cell (2023)
3. Car-Engineered Nk Cells; a Promising Therapeutic Option for Treatment of Hematological Malignancies, Stem Cell Research and Therapy (2021)
4. Preclinical Studies of Chimeric Antigen Receptor-Modified Natural Killer Cells in Cancer Immunotherapy: A Review, Expert Opinion on Biological Therapy (2022)
5. Car-Nk Cells: A Promising Cellular Immunotherapy in Lymphoma, Expert Opinion on Biological Therapy (2023)
6. Advances in Natural Killer Cell Therapies for Breast Cancer, Immunology and Cell Biology (2023)
7. The Tricks for Fighting Against Cancer Using Car Nk Cells: A Review, Molecular and Cellular Probes (2022)
8. Natural Killer Cell-Based Therapies in Neuroblastoma, Cellular Immunology (2025)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (22)
Hamid Reza Mirzaei (18)
Other Related Docs
9. Car-Nk Cell: A New Paradigm in Tumor Immunotherapy, Frontiers in Oncology (2021)
10. Natural Killer Cells and Acute Myeloid Leukemia: Promises and Challenges, Cancer Immunology# Immunotherapy (2022)
11. Cancer Immunotherapy Via Stem Cell-Derived Nk Cells, Immunotherapy (2023)
12. Car-Nk Cell in Cancer Immunotherapy; a Promising Frontier, Cancer Science (2021)
13. Highly Efficient Generation of Transgenically Augmented Car Nk Cells Overexpressing Cxcr4, Frontiers in Immunology (2020)
14. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells, Frontiers in Immunology (2018)
15. Car-Engineered Nk Cells Versus Car T Cells in Treatment of Glioblastoma; Strength and Flaws, Journal of Neuro-Oncology (2025)
16. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
17. Contribution of Natural Killer Cells in Innate Immunity Against Colorectal Cancer, Frontiers in Oncology (2023)
18. Programmable and Multi-Targeted Cars: A New Breakthrough in Cancer Car-T Cell Therapy, Clinical and Translational Oncology (2021)
19. Cancer Stem Cell-Targeted Chimeric Antigen Receptor (Car)-T Cell Therapy: Challenges and Prospects, Acta Pharmaceutica Sinica B (2021)
20. Genetically Modified Immune Cells Targeting Tumor Antigens, Pharmacology and Therapeutics (2020)
21. Natural Killer Cells and Cancer Therapy, What We Know and Where We Are Going, Immunotherapy (2019)
22. Car T Cell Therapy in Solid Tumors; With an Extensive Focus on Obstacles and Strategies to Overcome the Challenges, International Immunopharmacology (2021)
23. Novel Car T Therapy Is a Ray of Hope in the Treatment of Seriously Ill Aml Patients, Stem Cell Research and Therapy (2021)
24. Stem Cells-Derived Natural Killer Cells for Cancer Immunotherapy: Current Protocols, Feasibility, and Benefits of Ex Vivo Generated Natural Killer Cells in Treatment of Advanced Solid Tumors, Cancer Immunology# Immunotherapy (2021)
25. The Paths and Challenges of “Off-The-Shelf” Car-T Cell Therapy: An Overview of Clinical Trials, Biomedicine and Pharmacotherapy (2023)
26. Chimeric Antigen Receptor -T Cell Therapy: Applications and Challenges in Treatment of Allergy and Asthma, Biomedicine and Pharmacotherapy (2020)
27. The Efficacy and Applicability of Chimeric Antigen Receptor (Car) T Cell-Based Regimens for Primary Bone Tumors: A Comprehensive Review of Current Evidence, Journal of Bone Oncology (2024)
28. Therapeutic Roles of Car T Cells in Infectious Diseases: Clinical Lessons Learnt From Cancer, Reviews in Medical Virology (2022)
29. Recent Progress in Cancer Immunotherapy: Overview of Current Status and Challenges, Pathology Research and Practice (2023)
30. Production of Car T-Cells by Gmp-Grade Lentiviral Vectors: Latest Advances and Future Prospects, Critical Reviews in Clinical Laboratory Sciences (2019)
31. Remote Controlling of Car-T Cells and Toxicity Management: Molecular Switches and Next Generation Cars, Translational Oncology (2021)
32. The Role of the Natural Killer (Nk) Cell Modulation in Breast Cancer Incidence and Progress, Molecular Biology Reports (2022)
33. Natural Killer Cell–Based Immunotherapy: From Transplantation Toward Targeting Cancer Stem Cells, Journal of Cellular Physiology (2018)
34. Anti-Cd20 Antibody Treatment for B-Cell Malignancies, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2 (2023)
35. Unraveling the Dynamic Mechanisms of Natural Killer Cells in Viral Infections: Insights and Implications, Virology Journal (2024)
36. The Role of Nk Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia, Stem Cell Reviews and Reports (2023)
37. An Updated Overview of the Application of Car-T Cell Therapy in Neurological Diseases, Biotechnology Progress (2023)
38. Applications of Single-Cell Omics for Chimeric Antigen Receptor T Cell Therapy, Immunology (2024)
39. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
40. Car-T Cells: Early Successes in Blood Cancer and Challenges in Solid Tumors, Acta Pharmaceutica Sinica B (2021)
41. Outsmarting Trogocytosis to Boost Car Nk/T Cell Therapy, Molecular Cancer (2023)
42. Autoimmunity As a Target for Chimeric Immune Receptor Therapy: A New Vision to Therapeutic Potential, Blood Reviews (2020)
43. Therapeutic Approaches for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (All), a Review on Monoclonal Antibodies and Targeted Therapies, Indian Journal of Cancer (2022)
44. T Cell Engineered With a Novel Nanobody-Based Chimeric Antigen Receptor Against Vegfr2 As a Candidate for Tumor Immunotherapy, IUBMB Life (2019)
45. Antigen-Independent Killer Cells Prepared for Adoptive Immunotherapy: One Source, Divergent Protocols, Diverse Nomenclature, Journal of Immunological Methods (2020)
46. A Deep Insight Into Crispr/Cas9 Application in Car-T Cell-Based Tumor Immunotherapies, Stem Cell Research and Therapy (2021)
47. Cell-Based Vaccines: Frontiers in Medical Technology for Cancer Treatment, Regenerative Engineering and Translational Medicine (2024)
48. Natural Killer Cell-Derived Exosomes for Cancer Immunotherapy: Innovative Therapeutics Art, Cancer Cell International (2023)
49. Natural Killer Cell Epigenetic Reprogramming in Tumors and Potential for Cancer Immunotherapy, Epigenomics (2023)
50. Prospects for Chimeric Antigen Receptor (Car) Γδ T Cells: A Potential Game Changer for Adoptive T Cell Cancer Immunotherapy, Cancer Letters (2016)